LAI: Aripiprazole (Abilify) Maintena Comments.
Recently, an intramuscular long-acting injectable (LAI) depot formulation of aripiprazole (ABILIFY MAINTENA()) (aripiprazole LAI) has been approved for use as
First-generation and second-generation LAI antipsychotics, including the aripiprazole formulations (Abilify Maintena, Abilify Asimtufii
Sustenna Trinza Hafyera mnemonics. Aripiprazole LAI products: Maintena. Asimtufii. Aristada. Initio. Abilify Maintena mnemonic. Abilify
This guidance informs appropriate use of aripiprazole LAI while navigating the olanzapine LAI shortage. Abilify Maintena unapproved product.
Abilify Maintena (aripiprazole once-monthly LAI)1. If approved, aripiprazole 2-month RTU LAI would be the first 2-month LAI antipsychotic
This guidance informs appropriate use of aripiprazole LAI while navigating the olanzapine LAI shortage. Abilify Maintena unapproved product.
This guidance informs appropriate use of aripiprazole LAI while navigating the olanzapine LAI shortage. Abilify Maintena unapproved product.
First-generation and second-generation LAI antipsychotics, including the aripiprazole formulations (Abilify Maintena, Abilify Asimtufii
Comments
This was fantastic. Justice to a horrible situation generated by REMF's.
Thanks